Biomedcode is pleased to announce that, the T2EDK program -Spondylitis Evaluation Platform via non invasive Imaging Application tools (SEPIA)- initiated in collaboration with the developer of novel breakthrough imaging systems company BIOEMTECH, has been financed by the European Union and Greek national funds through the operational program Competitiveness, Entrepreneurship and Innovation under the call RESEARCH-CREATE-INNOVATE. SEPIA will combine the efforts of two innovative companies aiming to develop precision imaging tools for the evaluation of the severity of Spondyloarthritis pathology developed in the TgA86 established mouse model of the pathology. Integration of these imaging tools in the sprondyloarthritis drug efficacy evaluation platform will support the preclinical development of novel therapies for Spondyloarthritis.
